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In the present study, we have evaluated the in vitro antibacterial activity of essential oils
from Origanum vulgare, Thymus vulgaris, Lavandula angustifolia, Mentha piperita, and
Melaleuca alternifolia against 32 erythromycin-resistant [Mininum Inhibitory Concentration
(MIC) ≥1 μg/mL; inducible, constitutive, and efﬂux-mediated resistance phenotype;
erm(TR), erm(B), and mef (A) genes] and cell-invasive Group A streptococci (GAS) isolated
from children with pharyngotonsillitis in Italy. Over the past decades erythromycin
resistance in GAS has emerged in several countries; strains combining erythromycin
resistance and cell invasiveness may escape β-lactams because of intracellular location
and macrolides because of resistance, resulting in difﬁculty of eradication and recurrent
pharyngitis. Thyme and origanum essential oils demonstrated the highest antimicrobial
activity with MICs ranging from 256 to 512 μg/mL. The phenolic monoterpene carvacrol
[2-Methyl-5-(1-methylethyl) phenol] is a major component of the essential oils of Origanum
andThymus plants. MICs of carvacrol ranged from 64 to 256 μg/mL. In the live/dead assay
several dead cells were detected as early as 1 h after incubation with carvacrol at the
MIC. In single-step resistance selection studies no resistant mutants were obtained. A
synergistic action of carvacrol and erythromycin was detected by the checkerboard assay
and calculation of the Fractional Inhibitory Concentration (FIC) Index. A 2- to 2048-fold
reduction of the erythromycin MIC was documented in checkerboard assays. Synergy (FIC
Index ≤0.5) was found in 21/32 strains andwas highly signiﬁcant (p < 0.01) in strains where
resistance is expressed only in presence of erythromycin. Synergy was conﬁrmed in 17/23
strains using 24-h time-kill curves in presence of carvacrol and erythromycin. Our ﬁndings
demonstrated that carvacrol acts either alone or in combination with erythromycin against
erythromycin-resistant GAS and could potentially serve as a novel therapeutic tool.
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INTRODUCTION
The increase in antibiotic-resistant bacteria has revived the inter-
est in plant products as alternative/adjunct antimicrobial agents to
control pathogenic micro-organisms (Cowan, 1999; Hemaiswarya
et al., 2008; Hyldgaard et al., 2012). A major group of plant antimi-
crobial compounds is represented by essential oils, which are
complex mixtures of volatile secondary metabolites. They are used
in the food industry because of their preservative potency against
food-borne pathogens—thanks to their antimicrobial, antibac-
terial, and antifungal properties. Besides antimicrobial activity,
essential oils and their components can act in synergy with some
antibiotics, enhancing their antimicrobial activity (Langeveld
et al., 2014). Thephenolicmonoterpene carvacrol [2-Methyl-5-(1-
methylethyl) phenol, isomeric with thymol] is a major component
of the essential oils of plants of the Labiatae family, including
Origanum and Thymus, which are commonly used as season-
ing and in traditional medicine since ancient times (Nostro and
Papalia, 2012). Carvacrol has been classiﬁed as GRAS (Gener-
ally Recognized As Safe) and approved for food use (EAFUS,
2006; Hyldgaard et al., 2012; European Parliament and Council,
1996). Beside anti-inﬂammatory, antioxidant, antitumor, anal-
gesic, anti-hepatotoxic, and insecticidal properties, several studies
have demonstrated that carvacrol has antimicrobial properties
(Hyldgaard et al., 2012). Findings regarding the latter proper-
ties are the subject of a recent review (Hyldgaard et al., 2012).
The antibacterial action of carvacrol, which is stronger against
Gram-positive than Gram-negative bacteria, principally relies on
bacterial membrane damage; it results in dissolution of the proton
motive force and subsequent reduction in ATP synthesis that lead
to reduction in other energy-dependent cell processes, including
synthesis of enzymes and toxins (Nostro and Papalia, 2012). In
particular, carvacrol has extensively been tested as an antimicro-
bial agent in food to control Gram-positive and Gram-negative
pathogens, including Bacillus cereus, Enterococcus faecalis, Listeria
monocytogenes, Staphylococcus aureus, Escherichia coli O157:H7,
Pseudomonas ﬂuorescens, Salmonella typhimurium,Vibrio cholerae,
and V. vulniﬁcus (Hyldgaard et al., 2012; Langeveld et al., 2014).
The ability of carvacrol to exert synergistic effects in combina-
tion with a number of antibiotics, including macrolides, has been
recently reported (Langeveld et al., 2014).
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Erythromycin and related molecules are the second-line drugs
used to treat pharyngotonsillitis and other infections caused
by Streptococcus pyogenes [Group A streptococci (GAS)], an
important human pathogen. GAS cause a variety of clini-
cal manifestations ranging from non-invasive disease, such as
pharyngitis and impetigo, to more severe, invasive infections
including necrotizing fasciitis, sepsis, toxic shock-like syndrome,
and post-streptococcal sequelae such as acute rheumatic fever,
rheumatic heart disease, and glomerulonephritis (Cunningham,
2008). In particular, GAS are the most common bacterial cause
of pharyngotonsillitis in children. Over the past decades ery-
thromycin resistance in GAS has emerged in several countries,
including Italy (Kaplan and Cornaglia, 2005; Gracia et al., 2009).
At present, it has fallen dramatically in Europe and America,
while rates >90% have recently been reported in China (Chang
et al., 2010; Liang et al., 2012). Several genes are responsible
for erythromycin resistance in GAS (Giovanetti et al., 2002). An
efﬂux mechanism encoded by different macrolide efﬂux (mef)
genes causes resistance to 14- and 15-membered macrolides
(M phenotype); in contrast, ribosomal modiﬁcation by ery-
thromycin resistancemethylase (erm) genes causes co-resistance to
macrolide-lincosamide-streptogramin B (MLS) antibiotics. MLS
resistance is constitutive when it is encoded by the erm(B) gene
(cMLS phenotype); it is inducible, i.e., expressed only in pres-
ence of the antibiotic, when it is encoded by the erm(TR) or the
variant erm(B) gene (iMLS phenotype). An association between
erythromycin resistance and ability to invade and survive within
human respiratory cells has been documented in Italy among GAS
isolated from children with pharyngotonsillitis (Facinelli et al.,
2001): these strains may escape β-lactams because of intracellular
location and macrolides—which unlike β-lactams enter eukary-
otic cells and are active in intracellular compartments—because
of resistance, resulting in difﬁculty of eradication and recurrent
pharyngitis.
In this study, we evaluated the antibacterial activity of different
essential oils and of carvacrol, alone and in combination with
erythromycin, against erythromycin-resistant GAS isolated from
children with pharyngotonsillitis in Italy.
MATERIALS AND METHODS
GAS STRAINS AND GROWTH MEDIA
Test strains were 32 erythromycin-resistant [Mininum Inhibitory
Concentration (MIC) ≥1 μg/mL] GAS strains isolated from chil-
dren with pharyngotonsillitis in a nationwide survey in Italy
(Varaldo et al., 1999; Table 1). Erythromycin-resistant GAS
isolates were genotypically and phenotypically heterogeneous:
erm(TR)/iMLS (n = 6); erm(B)/iMLS (n = 6); erm(B)/cMLS
(n = 8); mef(A)/M (n = 12). The strains had previously been
investigated for the association between erythromycin resistance
and ability to enter and persist inside human respiratory A549
cells (Facinelli et al., 2001; Spinaci et al., 2004, 2006); they had
also been typed at the molecular level (Spinaci et al., 2004, 2006).
Each of the 32 strains included in the study represents a clone
identiﬁed among Italian erythromycin-resistant GAS. Blood agar
base (BAB) supplemented with 5% sheep blood, Müller-Hinton
agar (MHA) supplemented with 5% sheep blood, Müller-Hinton
cation-adjusted broth (CAMHB) supplemented with 3% laked
sheep blood, and brain heart infusion broth (BHIB; Oxoid, Bas-
ingstoke, UK) were used throughout the study. Isolates were
maintained in glycerol at −70◦C and sub-cultured twice on BAB
before testing.
ANTIMICROBIALS AND SUSCEPTIBILITY TESTS
Five different essential oils [origanum (W282812), thyme
(W306401), lavender (W262218), tea tree (W390208), and pep-
permint (W284815)], carvacrol (W224502, >98% purity), and
erythromycin (E-5389) were all purchased from Sigma–Aldrich
(St. Louis, MO, USA). Essential oils (10 mg/mL stock solutions)
were stored in DMSO at −20◦C; carvacrol and erythromycin
(10 mg/mL stock solutions) were stored in absolute ethanol at
−20◦C. MIC is deﬁned as the lowest concentration of an antimi-
crobial that will inhibit the visible growth of a microorganism
after overnight incubation. MICs of essential oils and carvacrol
were determined by agar dilution (in blood-supplemented MHA)
and microdilution (in blood-supplemented CAMHB) methods,
respectively, as recommended by Clinical and Laboratory Stan-
dards Institute [CLSI] (2014) guidelines. All experiments were
performed in triplicate.
LIVE/DEAD ASSAY
GroupA streptococci survival in presence of carvacrol was studied
by the live/dead assay as described previously (Zandri et al., 2012)
using SYBR Green I (Invitrogen, Eugene, OR, USA) and propid-
ium iodide (Sigma–Aldrich), two nucleic acid dyes differing in
their ability to penetrate bacterial cells: bacteria with intact cell
membranes stain ﬂuorescent green, whereas those with damaged
membranes stain ﬂuorescent red. Brieﬂy, overnight grown strep-
tococci were suspended in 1 mL carvacrol-supplemented BHIB
(∼1 × 108 CFU/mL) and incubated for 1, 3, or 24 h at 37◦C in 5%
CO2. After staining with 1 × SYBR Green I and 40 μg/mL pro-
pidium iodide, samples were incubated at room temperature for
25 min in the dark, harvested on GTBP ﬁlters (Ø = 0.2 μm, Milli-
pore, Billerica,MA,USA), and examined under an epiﬂuorescence
microscope (Axioskop 2, Zeiss, Milano, Italy).
CHECKERBOARD TEST
Synergy was tested by the checkerboard method, a two-
dimensional array of serial concentrations of test compounds,
that has been used most frequently to assess antimicrobial com-
binations in vitro (Pillai et al., 2005). The tested dilutions were
based on the MIC of the two substances. The checkerboard
test was used as the basis to calculate a Fractional Inhibitory
Concentration (FIC) Index (Pillai et al., 2005) according to the
formulas: FICA = MICA+B/MICA, FICB = MICB+A/MICB,
FIC Index = FICA+FICB. The MICA+B value is the MIC of
compound A in the presence of compound B, and vice versa
for MICB+A. FIC Index values were interpreted accordingly
to Odds (Odds, 2003): synergy (FIC Index ≤0.5), antago-
nism (FIC Index >4.0), and no interaction (FIC Index >0.5–
4.0).
The test was performed in blood-supplemented CAMHB using
96-wellmicrotiter plates containing erythromycin and carvacrol in
twofold serial concentrations. Bacterial suspensionswere prepared
to yield ﬁnal inocula of ∼5 × 105 CFU/mL. Plates were read after
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Table 1 | Characteristics of erythromycin-resistant GAS, each strain representing an erythromycin-resistant Italian GAS clone.
Genotype/phenotype of
erythromycin resistance
(no. of strains)
Mininum Inhibitory Concentration (MIC; μg/mL) Fractional Inhibitory Concentration (FIC) Index
ERYa CARb Best combinationc FIC ≤0.5 >0.5
ERYa CARb ERYa CARb
erm(TR)/iMLS (n = 6)
SP1900d 256 128 4 32 0.0156 0.2500 0.2656
SP1161 8 64 1 8 0.1250 0.1250 0.2500
SP55 8 128 0.5 32 0.0625 0.2500 0.3125
SP1160 16 128 4 8 0.2500 0.0625 0.3125
SP4502 64 128 16 8 0.2500 0.0625 0.3125
11613 8 64 2 16 0.2500 0.2500 0.5000
erm(B)/iMLS (n = 6)
SP1188 512 128 0.5 32 0.0009 0.2500 0.2509
11414 512 128 0.5 32 0.0009 0.2500 0.2509
11107 512 128 1 32 0.0019 0.2500 0.2519
SP1181 512 128 2 32 0.0039 0.2500 0.2539
SP114 512 128 0.5 32 0.0009 0.2500 0.2509
SP1189 512 64 0.25 32 0.0005 0.5000 0.5005
erm(B)/cMLS (n = 8)
SP2130 512 128 2 32 0.0039 0.2500 0.2539
10039 512 128 2 32 0.0039 0.2500 0.2539
SP9707 512 64 0.25 32 0.0005 0.5000 0.5005
SP9103 512 64 0.25 32 0.0005 0.5000 0.5005
37014 512 64 0.25 32 0.0005 0.5000 0.5005
SP1791 512 64 0.25 32 0.0005 0.5000 0.5005
SP1003 512 128 0.25 64 0.0005 0.5000 0.5005
SP1070 512 128 0.25 64 0.0005 0.5000 0.5005
mef (A)/M (n = 12)
10911 8 64 2 16 0.2500 0.2500 0.5000
SP9721 16 64 0.5 16 0.0313 0.2500 0.2813
9407 32 64 8 16 0.2500 0.2500 0.5000
SP1180 16 128 4 32 0.2500 0.2500 0.5000
10239 16 128 4 32 0.2500 0.2500 0.5000
SP118 16 256 0.5 64 0.0313 0.2500 0.2813
10244 16 128 4 32 0.2500 0.2500 0.5000
10313 16 128 4 32 0.2500 0.2500 0.5000
SP1013 1 128 0.25 64 0.2500 0.5000 0.7500
13962 16 128 0.5 64 0.0313 0.5000 0.5313
128–192 16 128 0.5 64 0.0313 0.5000 0.5313
SP1951 16 128 0.03 64 0.0019 0.5000 0.5019
aErythromycin; bCarvacrol; cCombination of carvacrol and erythromycin giving the lowest FIC Index value; d(Palmieri et al., 2006).
overnight incubation at 37◦C in 5% CO2. Each test was performed
in triplicate. Test results were also represented by isobolograms
constructedbyplotting synergistic concentrations of carvacrol and
erythromycin (Mulyaningsih et al., 2010).
TIME-KILL CURVES
Time-kill experiments were performed in BHIB in microtiter
plates containing different combinations of carvacrol and
erythromycin at different sub-MICs. Brieﬂy, streptococci
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(∼5 × 105 CFU/mL) were placed on microtiter plates, incubated
for 24 h at 37◦C and read at OD690 at 1-h intervals using Multiscan
Ascent (Thermo Scientiﬁc, Waltham, MA, USA). Controls also
included growth in presence of carvacrol and erythromycin alone.
All experiments were performed in triplicate.
SEARCH FOR CARVACROL MUTANTS
In these experiments, bacterial cells were grown overnight in BHI
agar plates, scraped off, washed once with BHIB, and resuspended
to a ﬁnal concentration of 1 × 1010 to 1 × 1011 CFU/mL. An
aliquot (50 μL) of bacterial suspension was spread on carvacrol-
containing BAB plates at 1, 2, and 4 times the MIC. The plates were
incubated at 37◦C in CO2 for 72 h. Experiments were repeated
twice.
STATISTICAL ANALYSIS
Synergy data were analyzed using Fisher’s exact test. Fisher’s test
was used to evaluate whether the association between pheno-
type iMLS and synergy in erm-carrying strains was signiﬁcant.
Signiﬁcance was set at p-value< 0.01.
RESULTS
The MICs of origanum and thyme oils ranged from 256 to
512 μg/mL, while those of lavender, tea tree, and peppermint
oils ranged from 1024 to >4096 μg/mL (Figure 1). The MICs of
carvacrol were 64 μg/mL (n = 10 strains), 128 μg/mL (n = 21
strains), and 256 μg/mL (n = 1 strain; Table 1). In the live/dead
assay several red cells were detected as early as 1 h after incubation
with carvacrol at the MIC (data not shown).
In the checkerboard assay, 77 different combinations of ery-
thromycin and carvacrol were tested for each strain, ranging
from several dilutions below the MIC to twice the MIC. A 2- to
2048-fold reduction of the erythromycin MIC was documented
in synergy tests with the checkerboard assay (Table 1). FIC Index
values were calculated by considering all combinations of car-
vacrol and erythromycin in which there was no visible growth.
The “best combination” of carvacrol and erythromycin, i.e., the
one giving the lowest FIC Index value, was indicated in Table 1.
FIC Index values ranged from 0.25 to 0.75 (Table 1). Synergy
(FIC Index ≤0.5) was detected in 21/32 strains (65.6%) and
no interaction (FIC Index >0.5) in the remaining 11 strains
(34.4%); antagonism was never observed. Strains where synergy
was detected included all 6 erm(TR)/iMLS, 5/6 erm(B)/iMLS, 2/8
erm(B)/cMLS, and 8/12 mef(A)/M isolates. Among erm-carrying
strains the association between the iMLS phenotype and syn-
ergy was very statistically signiﬁcant (p = 0.0044). Strains where
no interaction was detected included 8 strains with borderline
FIC Index values (0.5005, 0.5019). Isobolographic analysis con-
ﬁrmed a synergistic effect against strains with FIC Index ≤0.5
(Figure 2) and no interaction against those with FIC Index
>0.5, including those with borderline FIC Index values (data not
shown).
Synergy was also examined in 23 strains (18 strains with FIC
Index ≤0.5 and 5 strains with FIC Index >0.5) using 24-h time-
kill curves in presence of carvacrol and erythromycin. These
ﬁndings conﬁrmed the checkerboard data in 13/18 strains with
FIC Index ≤0.5 (8/9 iMLS, 1/1 cMLS, and 4/8 M; Figure 3A),
and in 4/5 strains with FIC Index >0.5 (1 cMLS, and 3 M;
Figure 3B). The time-kill curves of the two strains with border-
line FIC Index values (SP1951, FIC Index 0.5019; and SP1189,
FIC Index 0.5005) indicated a lack of interaction (Figures 3C,D),
even though synergy was seen in strain SP1189 in the ﬁrst
18 h (Figure 3D). The discrepancy between checkerboard
and time-kill data may depend on the media (with/without
blood) and/or growth conditions (with/without CO2) (Odds,
2003).
FIGURE 1 | Mininum Inhibitory Concentrations (MICs) of five essential oils against GAS strains.
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FIGURE 2 | Checkerboard test and isobolograms. (A,B) strain SP1161 [Fractional Inhibitory Concentration (FIC) Index = 0.2500]; (C,D) strain 10911 (FIC
Index = 0.5000). Shading, visible growth. CAR, carvacrol; ERY, erythromycin.
FIGURE 3 |Time-kill curves. (A) strain SP1900 (FIC Index = 0.2656). (B) SP1013 (FIC Index = 0.7500). (C) SP1951 (FIC Index = 0.5019). (D) SP1189 (FIC
Index = 0.5005). CAR, carvacrol; ERY, erythromycin.
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No carvacrol-resistant mutants were obtained in single-step
resistance selection experiments using strains SP2130, SP1188,
SP1900, and 10239.
DISCUSSION
One of the alternative strategies to ﬁght antibiotic-resistant bac-
teria is the use of natural antimicrobial substances such as
plant essential oils and their components. Another possibil-
ity is to combine existing antibiotics with phytochemicals to
enhance the efﬁcacy of antibiotics. Among others, essential oils
from Thymus vulgaris and Origanum vulgare contain carvacrol
and thymol, whose antibacterial activity and synergistic effect
in combination with antibiotics against food-related bacteria
have been demonstrated (Hyldgaard et al., 2012; Langeveld et al.,
2014).
In this study, the antimicrobial activity of ﬁve essential oils
from different plants was tested against pharyngeal GAS iso-
lates, all erythromycin-resistant and cell-invasive strains. The
antimicrobial activity of thyme and origanum oils was high,
with MICs much lower than those of lavender, mint, and
tea tree oils. Since carvacrol is a major component of thyme
and origanum essential oils, we decided to test the susceptibil-
ity of GAS strains to carvacrol. Our ﬁndings demonstrated a
high activity of carvacrol against GAS, with MICs lower than
those reported for other Gram-positive bacteria (Hyldgaard et al.,
2012). A bactericidal action of carvacrol, probably through mem-
brane damage, was suggested by the live/dead assay. Attempts
to select carvacrol-resistant mutants were unsuccessful, suggest-
ing that carvacrol is not prone to the development of resistance
in GAS.
To our knowledge the synergistic activity of carvacrol and
antibiotics against GAS has never been investigated, with
the exception of a recent study of a single erm(B) col-
lection strain (Palaniappan and Holley, 2010). Carvacrol
in combination with erythromycin showed a synergistic
action against tested GAS isolates; antagonism was never
observed.
Interestingly, synergy was highly signiﬁcant (p < 0.01) in
iMLS strains, in which erythromycin resistance is only expressed
in presence of an inducing sub-inhibitory concentration of the
antibiotic. The molecular basis of the synergy deserves further
investigation; an interference with the expression of the inducible
methyl-transferases gene or inhibition of the enzyme itself might
be involved in carvacrol’s synergistic action against iMLS GAS
strains.
Overall, results of the current study suggest a potential
use of origanum and thyme essential oils and of carvacrol
against GAS. Moreover, the evidence of a synergism between
erythromycin and carvacrol suggest a possible re-use of ery-
thromycin against erythromycin-resistant GAS. In particular,
carvacrol might be useful against those GAS strains which com-
bine erythromycin resistance and the ability to invade and
survive within human respiratory cells (Facinelli et al., 2001),
resulting in difﬁculty of eradication and recurrent pharyngi-
tis. With more knowledge of the mechanism underlying the
synergism it may be possible to develop safe drug combina-
tions.
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